+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism of Action, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism of Action, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism of Action, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968783
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multiple Sclerosis Market grew from USD 18.05 billion in 2024 to USD 19.59 billion in 2025. It is expected to continue growing at a CAGR of 8.28%, reaching USD 29.11 billion by 2030.

Navigating the Evolving Multiple Sclerosis Landscape

Multiple sclerosis stands at the nexus of groundbreaking medical innovation and enduring clinical challenges, with evolving therapeutic options reshaping the outlook for patients worldwide. As new mechanisms of action emerge alongside enhanced diagnostic tools, stakeholders must stay informed about shifting competitive dynamics, regulatory developments, and evolving patient needs. This executive summary distills the critical developments defining the current landscape, synthesizing evidence from diverse data sources to illuminate emerging trends and strategic imperatives.

By weaving together regulatory updates, technology-driven care models, and evolving payer expectations, this introduction sets the stage for a comprehensive analysis of transformative market forces. From the influence of upcoming tariff policies to nuanced segmentation insights and regional growth drivers, readers will gain a cohesive view of the factors shaping the multiple sclerosis arena. The following sections build upon this overview, offering actionable intelligence to support informed decision-making across research, commercial, and investment functions.

Emerging Disruptors Redefining MS Treatment Paradigms

Recent years have witnessed a profound reconfiguration of the multiple sclerosis treatment paradigm, driven by advances in molecular targeting, digital health integration, and real-world evidence generation. Precision medicine approaches are transitioning from conceptual frameworks to clinical reality, with therapies honed to patient subpopulations based on genetic markers and disease progression profiles. Simultaneously, digital therapeutics and telemedicine platforms are forging new pathways for remote monitoring, adherence support, and patient engagement, expanding the reach of specialized care beyond traditional clinic walls.

Regulatory bodies have accelerated review pathways for novel entities, shortening time to market for therapies that address unmet needs. This shift has catalyzed early adoption of high-efficacy treatments but also introduced pricing and reimbursement complexities. Payers are increasingly demanding robust outcome data to justify coverage, prompting a surge in value-based contracting models. Meanwhile, collaborations between established pharmaceutical companies and agile biotech firms are unlocking synergies across discovery, development, and commercialization, redefining the competitive landscape. These converging forces signal a transformative era in which agility, strategic partnerships, and data-driven insights will determine leadership in multiple sclerosis care.

Evaluating the Ripple Effects of US Tariffs on MS Therapies

The introduction of cumulative United States tariffs slated for 2025 has injected a new layer of complexity into the multiple sclerosis supply chain. Manufacturers reliant on imported active pharmaceutical ingredients face incremental cost pressures that may ripple through to contract manufacturers, distributors, and ultimately patients. These tariffs are projected to exacerbate raw material shortages, heighten inventory risks, and compel companies to reassess sourcing strategies across global networks.

In response, leading organizations are implementing risk mitigation frameworks that include nearshoring critical API production and diversifying supplier portfolios. Negotiations with payers are evolving to incorporate tariff-related cost adjustments, while commercial teams explore tiered pricing structures to balance affordability with margin preservation. At the same time, research and development budgets are being reallocated to safeguard pipeline continuity, prioritizing programs with the highest clinical and commercial potential. These strategic shifts underscore the importance of proactive supply chain governance and dynamic pricing strategies to navigate the tariff-induced headwinds of 2025.

Unveiling Critical Patient and Therapy Segmentation Insights

A granular segmentation analysis reveals distinct dynamics across patient populations, therapeutic mechanisms, and care delivery channels. When examining multiple sclerosis by type, relapsing remitting disease commands significant attention due to its prevalence and the breadth of targeted therapies, while primary progressive and secondary progressive forms drive innovation in neuroprotective and reparative modalities. Dissecting the market by mechanism of action highlights the ascent of sphingosine 1 phosphate receptor modulators-such as fingolimod, ozanimod, ponesimod, and siponimod-alongside established immunomodulators like glatiramer acetate and interferons. Meanwhile, immunosuppressants exemplified by mitoxantrone and a growing arsenal of monoclonal antibodies-including alemtuzumab, natalizumab, ocrelizumab, and ofatumumab-underscore the trend toward highly targeted biologics.

Route of administration further influences patient adherence and commercial performance, with injectable options maintaining a foothold even as oral and intravenous therapies gain ground. Distribution channels span hospital and retail pharmacies as well as specialized online platforms, each offering unique efficiencies and patient engagement opportunities. Finally, treatment access within home care settings, hospitals, and specialty clinics shapes service delivery models and reimbursement dynamics. These intersecting segmentation insights provide a multidimensional perspective essential for crafting tailored market strategies and optimizing resource allocation.

Regional Dynamics Shaping MS Market Trajectories

Across geographies, regional drivers exert a powerful influence on multiple sclerosis market evolution. In the Americas, robust R&D infrastructure and early access programs have fostered rapid uptake of high-efficacy therapies, while evolving reimbursement frameworks are placing greater emphasis on long-term outcomes and real-world performance data. The Europe, Middle East & Africa region, characterized by diverse regulatory environments and varying healthcare capacities, presents both opportunities for localized clinical adoption and challenges in harmonizing patient access across national formularies.

The Asia-Pacific landscape is defined by emerging markets where epidemiological awareness is rising in tandem with healthcare investment. Governments and private payers are increasingly recognizing the socio-economic burden of multiple sclerosis, driving expansions in diagnostic capabilities and reimbursement policies. As digital health platforms proliferate, telemedicine and mobile health applications are bridging gaps in specialist care, creating new channels for remote monitoring and patient support. Understanding these regional nuances is critical for calibrating product launches, partnership models, and market entry strategies.

Profiling Trailblazers Driving Innovation in MS Care

Industry leaders are forging ahead with bold investments and strategic collaborations to address unmet needs and sustain competitive advantage. Established pharmaceutical companies are bolstering their pipelines through acquisitions and licensing deals, securing access to promising compounds targeting neuroinflammation and remyelination. Biotech innovators leverage agile development platforms to accelerate first-in-class modalities, while contract research organizations expand capacity for adaptive clinical trial designs that optimize patient enrollment and endpoint validation.

Cross-sector partnerships are redefining value creation, with technology firms integrating artificial intelligence and machine learning into diagnostic imaging and disease progression modeling. Simultaneously, patient advocacy groups are forging alliances with commercial stakeholders to co-design support programs and real-world study protocols. This dynamic ecosystem-anchored by leading therapeutics developers, technology disruptors, and patient-centric coalitions-underscores the collaborative imperatives driving the next wave of multiple sclerosis breakthroughs.

Strategic Imperatives for Advancing MS Industry Leadership

To capitalize on market transformation, industry leaders must embrace strategic imperatives that align innovation with stakeholder expectations. Prioritizing real-world evidence collection through post-authorization studies and patient registries will strengthen value propositions and facilitate favorable reimbursement negotiations. Investing in digital engagement platforms can enhance adherence, support remote monitoring, and unlock patient-reported outcomes that inform continuous improvement. Moreover, adopting value-based contracting models tied to clinical benchmarks will differentiate offerings in a competitive landscape increasingly defined by outcome accountability.

Companies should also explore strategic alliances with diagnostics providers and tech-enabled service firms to expand complementary capabilities. Nearshoring or regionalizing supply chains will mitigate tariff and logistics risks while enhancing responsiveness to local market requirements. Finally, cultivating cross-functional teams that integrate medical, commercial, and access experts will accelerate strategic alignment and ensure that product life-cycle management remains agile in the face of evolving regulatory and payer landscapes.

Rigorous Methodological Framework Underpinning the Analysis

This analysis draws on a rigorous methodological framework combining both secondary and primary research. Secondary sources included peer-reviewed journals, regulatory filings, clinical trial registries, and industry white papers, ensuring a comprehensive synthesis of published evidence. Primary research entailed structured interviews with key opinion leaders, payers, clinicians, and patient advocacy representatives, capturing nuanced perspectives on therapeutic value, access barriers, and emerging care models.

Quantitative data collection was supplemented by qualitative insights, with findings triangulated across multiple datasets to validate trends and projections. Segmentation hypotheses were tested through statistical analysis, and regional market dynamics were corroborated with localized expert feedback. This multi-layered approach ensures the robustness and reliability of the strategic insights presented throughout this report.

Synthesis of Key Findings and Forward-Looking Perspectives

This executive summary has highlighted the pivotal trends reshaping the multiple sclerosis market, from biology-driven therapeutic innovations to the strategic responses prompted by upcoming tariff policies. Segmentation analysis has clarified the distinct dynamics across disease types, mechanisms of action, care settings, and distribution channels. Regional profiles have illuminated divergent access pathways and growth drivers in the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Looking ahead, the confluence of precision medicine, digital health, and value-based contracting will continue to redefine stakeholder expectations and competitive benchmarks. Organizations that proactively integrate real-world insights, agile supply chain strategies, and cross-sector collaborations will be best positioned to capture emerging opportunities and deliver sustainable patient impact. This synthesis of findings underscores the critical need for informed, agile decision-making in the pursuit of breakthroughs that improve outcomes for individuals living with multiple sclerosis.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Multiple Sclerosis Type
    • Primary Progressive
    • Relapsing Remitting
    • Secondary Progressive
  • Mechanism Of Action
    • Fumarate Therapies
    • Immunomodulators
      • Glatiramer Acetate
      • Interferons
    • Immunosuppressants
      • Mitoxantrone
    • Monoclonal Antibodies
      • Alemtuzumab
      • Natalizumab
      • Ocrelizumab
      • Ofatumumab
    • Sphingosine 1 Phosphate Receptor Modulators
      • Fingolimod
      • Ozanimod
      • Ponesimod
      • Siponimod
  • Route Of Administration
    • Injectable
    • Intravenous
    • Oral
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Biogen Inc.
  • Novartis AG
  • Roche Holding AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Merck KGaA
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multiple Sclerosis Market, by Multiple Sclerosis Type
8.1. Introduction
8.2. Primary Progressive
8.3. Relapsing Remitting
8.4. Secondary Progressive
9. Multiple Sclerosis Market, by Mechanism of Action
9.1. Introduction
9.2. Fumarate Therapies
9.3. Immunomodulators
9.3.1. Glatiramer Acetate
9.3.2. Interferons
9.4. Immunosuppressants
9.4.1. Mitoxantrone
9.5. Monoclonal Antibodies
9.5.1. Alemtuzumab
9.5.2. Natalizumab
9.5.3. Ocrelizumab
9.5.4. Ofatumumab
9.6. Sphingosine 1 Phosphate Receptor Modulators
9.6.1. Fingolimod
9.6.2. Ozanimod
9.6.3. Ponesimod
9.6.4. Siponimod
10. Multiple Sclerosis Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.3. Intravenous
10.4. Oral
11. Multiple Sclerosis Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Multiple Sclerosis Market, by End User
12.1. Introduction
12.2. Home Care Settings
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Multiple Sclerosis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Multiple Sclerosis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Multiple Sclerosis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Biogen Inc.
16.3.2. Novartis AG
16.3.3. Roche Holding AG
16.3.4. Sanofi S.A.
16.3.5. Teva Pharmaceutical Industries Ltd.
16.3.6. Bristol-Myers Squibb Company
16.3.7. Merck KGaA
16.3.8. Bayer AG
16.3.9. Pfizer Inc.
16.3.10. Johnson & Johnson
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MULTIPLE SCLEROSIS MARKET MULTI-CURRENCY
FIGURE 2. MULTIPLE SCLEROSIS MARKET MULTI-LANGUAGE
FIGURE 3. MULTIPLE SCLEROSIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GLATIRAMER ACETATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MITOXANTRONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ALEMTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY NATALIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OCRELIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OFATUMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 66. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 67. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 68. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 69. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 119. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 121. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 123. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 128. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 130. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 131. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 132. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 146. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 148. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 149. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 150. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 151. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 155. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 156. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 157. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 158. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 159. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 191. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 193. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 194. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 195. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 209. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 210. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 211. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 212. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 213. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 214. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 218. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 220. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 245. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 246. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 247. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 248. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 249. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 254. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 255. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 256. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 257. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 258. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 272. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 274. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 275. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 276. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 281. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 282. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 283. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 284. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 285. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 286. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 308. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 309. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 310. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 311. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 312. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 313. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 314. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 316. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 318. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 319. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 320. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 321. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION

Companies Mentioned

The companies profiled in this Multiple Sclerosis market report include:
  • Biogen Inc.
  • Novartis AG
  • Roche Holding AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Merck KGaA
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 19.59 Billion
Forecasted Market Value ( USD ) by 2030 $ 29.11 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Multiple Sclerosis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Multiple Sclerosis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 97 Pages
  • Global
From
Relapsing Remitting Multiple Sclerosis Market - Product Image

Relapsing Remitting Multiple Sclerosis Market

  • Report
  • 250 Pages
  • Global
From
Chronic Progressive Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Progressive Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Relapsing-Remitting Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Relapsing-Remitting Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Multiple Sclerosis Drugs - Global Strategic Business Report - Product Image

Multiple Sclerosis Drugs - Global Strategic Business Report

  • Report
  • 235 Pages
  • Global
From

About the Multiple Sclerosis Drug Market

The Multiple Sclerosis (MS) Drug market is a subset of the Central Nervous System (CNS) Drugs market. MS is a chronic, progressive neurological disorder that affects the central nervous system, causing a wide range of physical and mental symptoms. MS drugs are used to reduce the frequency and severity of MS relapses, slow the progression of the disease, and improve the quality of life of those affected. MS drugs are typically divided into two categories: disease-modifying therapies (DMTs) and symptomatic therapies. DMTs are used to slow the progression of the disease, while symptomatic therapies are used to manage the symptoms of MS. Common DMTs include interferon beta, glatiramer acetate, fingolimod, and natalizumab. Common symptomatic therapies include muscle relaxants, antispasmodics, and antidepressants. The MS Drug market is highly competitive, with a number of major pharmaceutical companies competing for market share. Some of the major players in the market include Biogen, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.